Boralex (TSE:BLX – Free Report) had its target price lowered by CIBC from C$43.00 to C$42.00 in a report published on Friday,BayStreet.CA reports.
A number of other brokerages have also issued reports on BLX. Raymond James upped their target price on shares of Boralex from C$38.00 to C$41.00 in a research note on Thursday, August 15th. BMO Capital Markets boosted their target price on shares of Boralex from C$39.00 to C$46.00 in a research note on Thursday, September 5th. Cormark increased their price target on Boralex from C$45.00 to C$47.00 in a research note on Thursday, August 15th. Royal Bank of Canada raised their price objective on shares of Boralex from C$36.00 to C$38.00 in a research note on Thursday, August 15th. Finally, Cibc World Mkts upgraded shares of Boralex to a “strong-buy” rating in a research report on Monday, July 22nd. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Boralex presently has a consensus rating of “Buy” and an average price target of C$43.38.
Read Our Latest Analysis on Boralex
Boralex Stock Performance
Boralex Company Profile
Boralex Inc, together with its subsidiaries, engages in the development, construction, and operation of renewable energy power facilities in Canada, France, the United States, and the United Kingdom. It generates electricity from wind, solar, and hydroelectric resources. As of December 31, 2023, the company operates 100 wind farms; 12 solar energy facilities; 15 hydroelectric power stations; and 2 storage units with an installed capacity of 1,819 megawatts (MW) in North America and 1,259 MW in Europe.
Featured Stories
- Five stocks we like better than Boralex
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Warren Buffett, Cathie Wood Own Nu Holdings, Should You?
- Market Cap Calculator: How to Calculate Market Cap
- MercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?
- What is the Dogs of the Dow Strategy? Overview and Examples
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
Receive News & Ratings for Boralex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boralex and related companies with MarketBeat.com's FREE daily email newsletter.